Adjuvant Nivolumab Boosts Survival Outcomes in Muscle-Invasive Bladder Cancer

(MedPage Today) -- SAN FRANCISCO -- Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of the use of neoadjuvant chemotherapy, according to updated analyses of the CheckMate...